(Reuters) - The agency grants priority review to products that are considered to be potentially significant therapeutic advancements over existing therapies.
With priority review status, the U.S. Food and Drug Administration will make its decision on whether to approve the drug within six months, rather than the usual 10- to 12-month review period.
Read more at Reuters.com Government Filings News
With priority review status, the U.S. Food and Drug Administration will make its decision on whether to approve the drug within six months, rather than the usual 10- to 12-month review period.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment